Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Diseases 1High Grade Serous Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × ceralasertib × Clear all
NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡